Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden

International Journal of Clinical Practice

Volumn 59, Issue 10, 2005, Pages 1143-1152

  Quilici, S ^a   Chancellor, Jeremy ^a   Maclaine, G ^b   Mcguire, A ^c   Andersson, D ^d,e   Chiasson, J L ^f  

^a Innovus Research UK Ltd   (United Kingdom)

^b Bayer plc UK   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d UPPSALA UNIVERSITY   (Sweden)

^e National Board of Health and Welfare   (Sweden)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Costs and cost analysis; Diabetes mellitus; Economics; Hypoglycemic agents; NB; Pharmaceutical; Pre diabetic state; Randomised controlled trials; Type II

Indexed keywords

ACARBOSE; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; SWEDEN; AGED; COST BENEFIT ANALYSIS; ECONOMICS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MIDDLE AGED; STATISTICS;

ACARBOSE; AGED; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SWEDEN;

EID: 33644834261     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00629.x     Document Type: Article

References (20)

1. World Health Organisation. Diabetes: The cost of diabetes. (Available from http://www.who.int/mediacentre/factsheets/fs236/en/). Site accessed on 14-9-2004.
2. Diabetes Atlas. Brussels: International Diabetes Federation 2004.
3. Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS, Ekbom A. Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. J Clin Epidemiol 2001; 54: 802-9.
4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-94.
6. WHO Study Group. Diabetes Mellitus. WHO Tech Rep Ser 2004; 727: 7-113.
7. LFNAR. General Guidelines for economic evaluations from the pharmaceutical benefits board. (Avalilable at http://www.lfn.se/documents/in%20english/eng). Site accessed on 14-9-2004.
8. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: Do we need the oral glucose tolerance test? Ann Intern Med 2002; 136: 575-81.
9. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8.
10. Henriksson F, Agardh CD, Berne C et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000; 248: 387-96.
11. Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stroke. the case of Sweden. J Intern Med 1999; 246: 151-9.
12. Vårdprogram Hjärta Dalarna. (Available at http://www.algonet.se/~andersae/dalacardiologi/vardprog.html). Site accessed on 14-9-2004.
13. Brandstrom H, Erhardt L, Hedback B et al. Quality assurance of secondary prevention of coronary artery disease. Ongoing project offers possibilities for improved treatment. Läkartidningen 2004; 98: 4846-52.
14. Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: Costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003; 253: 472-80.
15. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 2004; 351: 1755-62.
16. Sweden statistics. Consumer Price Index. (Available at http://www.scb.se/). Site accessed on 14-9-2004.
17. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003; 21: 543-64.
18. Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diabet Med 2004; 21: 1229-36.
19. Hernan WH, Brandle M, Zhang P et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003; 26: 36-47.
20. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance. modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004; 26: 304-21.